In Friday’s premarket session, shares of Cidara Therapeutics Inc. (CDTX) rose 7.43% to $1.59. Cidara stock lost -2.63% last trading session to finish at $1.48. On the day, CDTX stock traded 0.36 million shares, which was less than the average daily volume of 0.4 million shares over the last 50 days. Shares of Cidara stock fell -4.52% over the last five days, but they lost -27.09% over the last month.
During the last three months, CDTX’s stock price has declined by -35.37%, and so far this year it has shed -26.00 percent. In the premarket session, CDTX stock gained traction as the company plans to present its clinical data at an international congress.
Where will Cidara be presenting?
Cidara develops long-acting therapeutics designed to improve the care of patients suffering from serious fungal or viral infections. As part of CDTX’s portfolio, Cidara has rezafungin, its lead antifungal candidate, plus AVCs targeting influenza and other viral diseases based on CDTX’s proprietary Cloudbreak antiviral platform. Cidara has its headquarters in San Diego, California.
In a statement released this week, Cidara announced that it will present clinical and preclinical data at the 2021 World Congress of the International Society for Human and Animal Mycology (ISHAM).
- This presentation will include data from CDTX’s Phase 2 STRIVE study as well as data evaluating rezafungin’s activity against Candida and Aspergillus species in vitro.
- These isolates were collected from Asian countries. Rezafungin, a once-weekly echinocandin from CDTX, is currently being evaluated in Phase 3 clinical trials for treating and preventing serious fungal infections in critical patients.
- A new conference in the field of medical mycology, ISHAM Asia aims to increase opportunities for local healthcare professionals and researchers by enabling them to interact with prominent researchers throughout the globe.
- Pre-Recorded co-sponsored presentation followed by live Q&A session will be held on Friday, August 6, 2021 at 6:00 am ET.
- Taylor Sandison, Chief Medical Officer of CDTX will be presenting and answering the question of presentation titled “Rezafungin: A novel, once-weekly echinocandin in phase 3 development for treatment and prevention of invasive fungal disease”.
CDTX’s other presentation:
Another activity by CDTX will be an e-poster presentation by CDTX’s Chief Medical Officer, having title: “Activity of rezafungin against clinical Candida and Aspergillus spp. isolates collected in Asia-Pacific (AP) countries (2014-2018)”. Cidara (CDTX) will make copies of the presentations available on the publications section of the company’s website.
